Aripiprazole shortage — US supply status & alternatives

Aripiprazole

ATC N05AX12

🇦🇺 AUST R 325485 · Cipla Australia Pty Ltd

In shortage · Australia

AbilifyAripiprazole EGARIPENA aripiprazoleAripiprazol Mylan Pharma

In declared shortage · 🇦🇺 Australia & also short in🇺🇸 US🇨🇦 CA🇧🇪 BE🇬🇷 GR

Critical shortage

Product discontinued / no longer available on the Australian market.

Reading today’s signals…

🇦🇺 AUAEMPA$23.55DPMQ A$38.92details →

✓ Can I substitute?

Per normal rules

Confirm with prescriber

⇄ Best alternative

None listed

refer to prescriber

Expected back

Product attributes reference data we hold

Active ingredient (INN)	Aripiprazole
Brand names	Abilify, Aripiprazole EG, ARIPENA aripiprazole, Aripiprazol Mylan Pharma
ATC level 5	N05AX12
ATC level 4	N05AX
Therapeutic category	Auto-created by Federal Agency for Medicines and Health Products — PharmaStatus scraper
Controlled substance	No
Marketing-authorisation holders	Cipla Australia Pty Ltd, Alembic Pharmaceuticals Australia Pty Ltd, Medis Pharma Pty Ltd, Lundbeck Australia Pty Ltd +1 more
Registrations on file	25
Patient information leaflet (PIL)	Not on file
Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 PBS · July 2026

🇦🇺 AU

● Official price on file

Ex-manufacturer

A$23.55

AEMP

Dispensed (DPMQ)

A$38.92

incl. fees

Pack

aripiprazole 10 mg tablet, 30

Source: PBSEffective July 2026 · AUD

Other markets

🇬🇧 GB

£1.15

Drug Tariff

🇺🇸 US

US$0.17

Acquisition

🇫🇷 FR

€43.07

Retail price

🇮🇹 IT

€19.50

Retail price

Global API supply base 🇺🇸 FDA Drug Master Files · active Type II

41 API manufacturers

Manufacturers with an active Type II Drug Master File — i.e. cleared to supply this active ingredient into the US market. A proxy for how concentrated the global manufacturing base is.

Low concentration risk

Cambrex Charles City INCSms Pharmaceuticals LTDVasudha Pharma Chem LTDZaklady Farmaceutyczne Polpharma SAYangtze River Pharmaceutical Group Jiangsu Haici Biological Pharmaceutical CO LTDChromo Laboratories India Private LTD+35 more

Manufacturing countries: United States, India, Poland, China, Italy, Canada, France · Source: FDA List of Drug Master Files

Recalls official enforcement reports

🇺🇸

ARIPIPRAZOLE

Ascend Laboratories, LLC · Aug 2025

Class IIdetails ↗

🇺🇸

ABILIFY

Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd. · Apr 2024

Class IIIdetails ↗

🇺🇸

ABILIFY

Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd. · Apr 2024

Class IIIdetails ↗

🇺🇸

ABILIFY

Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd. · Apr 2024

Class IIIdetails ↗

🇺🇸

ABILIFY

Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd. · Apr 2024

Class IIIdetails ↗

🇺🇸

Aripiprazole

RemedyRepack Inc. · Mar 2023

Class IIdetails ↗

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders25 registrations · 5 MA holders

Product	Strength	Form	Market	MA holder	Status
Aripic	5 mg	—	🇦🇺 AU	Cipla Australia Pty Ltd	Active
Aripic	15 mg	—	🇦🇺 AU	Cipla Australia Pty Ltd	Active
Arivel	15 mg	—	🇦🇺 AU	Alembic Pharmaceuticals Australia Pty Ltd	Active
Aripic	10 mg	—	🇦🇺 AU	Cipla Australia Pty Ltd	Active
Alembic	10 mg	—	🇦🇺 AU	Alembic Pharmaceuticals Australia Pty Ltd	Active
Aripic	20 mg	—	🇦🇺 AU	Cipla Australia Pty Ltd	Active
Alembic	5 mg	—	🇦🇺 AU	Alembic Pharmaceuticals Australia Pty Ltd	Active
Arivel	20 mg	—	🇦🇺 AU	Alembic Pharmaceuticals Australia Pty Ltd	Active
Alembic	30 mg	—	🇦🇺 AU	Alembic Pharmaceuticals Australia Pty Ltd	Active
Medis	15mg	tabuc	🇦🇺 AU	Medis Pharma Pty Ltd	Active
Aripic	30 mg	—	🇦🇺 AU	Cipla Australia Pty Ltd	Active
Arivel	10 mg	—	🇦🇺 AU	Alembic Pharmaceuticals Australia Pty Ltd	Active
Arivel	30 mg	—	🇦🇺 AU	Alembic Pharmaceuticals Australia Pty Ltd	Active
Arivel	5 mg	—	🇦🇺 AU	Alembic Pharmaceuticals Australia Pty Ltd	Active
ABILIFY MAINTENA aripiprazole	300 mg	—	🇦🇺 AU	Lundbeck Australia Pty Ltd	Active

+10 more registrations on file

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.